MDGL logo

MADRIGAL PHARMACEUTICALS INC

MDGLNASDAQ
πŸ† #865 by market capEarnings Feb 17 Β· PostUS Equity
β€”β€”
Quote unavailable
πŸ””
Track MDGL
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$8.81B
Small Cap
πŸ“ˆRevenue Growth (YoY)
92.8%
High Growth
πŸ“ŠGross Margin
91.0%
High
πŸ’΅FCF Margin
9.5%
Moderate
βš–οΈP/S Ratio
6.2x
Fair
Otter Score
72
Strong
No chart data available for MDGL.

Trading Snapshot

Day Range
β€”
52-Week Range
$353.54 – $615.00
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
23.1M
Next Earnings
2027-02-17

Fundamentals Snapshot

Annual Revenue
$958M
Last Q Revenue
$431M
P/E Ratio
β€”
P/S Ratio
6.2x
EPS (TTM)
$-5.96
Dividend Yield
β€”
Dilution (1yr)
+2.3%
MDGL logo

MADRIGAL PHARMACEUTICALS INC

MDGL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$958Mβ–² +432.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
94.1%β–Ό βˆ’2.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$300Mβ–Ό βˆ’39.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$190Mβ–Ό βˆ’58.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
22.4Mβ–² +2.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$156Mβ–Ό βˆ’$136M YoY
StockOtter Β· stockotter.space

About MADRIGAL PHARMACEUTICALS INC

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100
Analyst data unavailable.

Latest News & Updates

News unavailable.